Since 2008, downstream purification issues have become progressively more acute problems for biomanufacturers. But that’s begun to change this year, according to results from BioPlan Associates’ 9th ...
The single-use downstream bioprocessing market presents opportunities through enhanced operational flexibility, reduced downtime, and sustainability. Key drivers include the demand for efficient ...
Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...
Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...
Downstream processing encompasses the sequence of operations required to isolate, purify and formulate a biopharmaceutical product from crude biological feedstock. Following cell culture or ...
In this brochure, Thermo Scientific takes a closer look at how integrated hot-melt extrusion (HME) workflows, paired with flexible downstream processing technologies from Thermo Fisher Scientific, can ...
Purifying novel therapeutics remains a major challenge as increasingly complex molecules move towards the clinic. With Lonza, you can ensure optimal product quality and bring your molecules to the ...
Sustainable bioprocessing filtration has moved from an aspirational goal to an operational priority as the scale and cost of water, buffer, and solvent consumption in biopharma manufacturing come ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results